natgillin/translations-raw huggingface dataset:
Use of an activator composition as defined in claim 11, comprising the step of adding to the hydraulically-active material a predetermined quantity of the activator composition contained in a package, preferably a water-soluble package. 
Uporaba pripravka aktivatora kako je definiran u zahtjevu 11, naznačena time što obuhvaća korak dodavanja hidrauličkom aktivnom materijalu unaprijed određene količine pripravka aktivatora koji se nalazi u pakiranju, poželjno u pakiranju topljivom u vodi.
The processing fluid of Claim 4, further comprising a sulfur-containing compound; wherein the sulfur-containing compound is elemental sulfur, a sulfurized mineral oil, or a compound of formula: wherein: R1 is H, SO4, NH2, CH3, COOH, OCH3, or OCH2CH3. 
Tekućina za obradu prema zahtjevu 4, naznačena time što nadalje sadrži spoj koji sadrži sumpor; pri čemu spoj koji sadrži sumpor je elementarni sumpor, sumporirano mineralno ulje, ili spoj s formulom: HR P20181311 T1 -&H
the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide that is amplifiable by polymerase chain reaction (PCR) on a human DNA sample using specific primers SEQ ID NO:3 and SEQ ID NO:4; (viii) the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1; 
(ili) sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su pojačani lančanom reakcijom polimeraze (PCR) na humanom DNA uzorku koristeći specifične primere SEQ ID NO:3 i SEQ ID NO:4; (iv) sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO: 1;
The process of any of the previous claims, wherein the feed water is desalinated seawater, brackish water or brine, treated wastewater or natural water such as ground water, surface water or rainfall. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je ulazna voda desalinirana morska voda, boćata voda ili rasol, obrađena otpadna voda ili prirodna voda poput podzemne vode, površinske vode 1li kišnice.
The pharmaceutical composition as claimed in Claim 9, which is for anti-rheumatoid arthritis. 
Farmaceutski sastav za uporabu prema zahtjevu 9, naznačen time, da treba djelovati protiv reumatoidnog artritisa.
By means of said gluing of 11 boards, a block of wood resulted having a height of 154 mm. 
Navedenim lijepljenjem 11 ploča stvoren je blok od drva koji ima visinu od 154 mm.
The topical veterinary composition of claim 7, wherein the at least second active agent is an anthelmintic active agent selected from thiabendazole, oxibendazole, mebendazole, fenbendazole, oxfendazole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an aryloazol-2-yl cyanoethylamino active agent. 
Topikalni veterinarski pripravak prema zahtjevu 7, naznačen time, da najmanje druga djelatna tvar je antihelmintska djelatna tvar odabrana od tiabendazola, oksibendazola, mebendazola, fenbendazola, oksfendazola, albendazola, triklabendazola, febantela, levamisola, pirantela, morantela, prazikvantela, klozantela, klorsulona, djelatne tvari aminoacetonitrila, i djelatne tvari ariloazol-2-il-cijanoetilamina.
The solvent was evaporated at reduced pressure at a temperature below 30 °C. The resulting aqueous residue (about 200 mL) was extracted with 4 x 500 mL chloroform. 
Otapalo se ispari pod smanjenim tlakom pri temperaturi ispod 30%C. Dobiveni vodeni ostatak (pribl. 200 mL) se ekstrahira sa 4 x 500 mL kloroforma.
The mixture was stirred at reflux temperature for one hour. 
Smjesa je miješana na temperaturi refluksa tijekom 1 sata.
A first aspect of the disclosure is a method for producing a laminated product, for example a building panel, preferably a floor panel, wherein the method comprising the steps of: 
HR P20171787 T1 PATENTNI ZAHTJEVI Metoda za proizvodnju laminiranog proizvoda, na primjer građevinskog panela, poželjno podnog panela (P), gdje metoda sadrži korake:
plotting a net charge versus pH curve at a selected temperature based on the amino acid composition of the polypeptide, and 
grafikon koji opisuje neto naboj naspram pH krivulje pri odabranoj temperaturi na temelju sastava aminokiselina polipeptida, i
A-compound having a formula selected from the group consisting of: and 
Spoj naznačen time da ima formulu odabranu iz skupine koju čine: [image] [image] i [image]
The pharmaceutical composition of claims 2 or 3, wherein Ar1 is 3-pyridyl or phenyl. 
Farmaceutska kompozicija iz patentnih zahtjeva 2 ili 3, gdje Ar, je 3-piridil ili fenil.
The process of claim 1, wherein said second solvent is selected from the group consisting of ethers, ketones, esters, amides, sulfoxides, aliphatic hydrocarbons, aromatic hydrocarbons, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine alkohols, eteri, ketoni, esteri, ksilen i N-metilpirolidinon, te smjese 2 ili više njih.
identifying, by the at least one server processor, an entry affiliated with said target record, said entry pertaining to said at least one set of connected controlled credentials; and permitting, by the at least one server processor, a retrieval of said at least one set of connected controlled credentials pertaining to said entry and permitting a release of said set of connected controlled credentials to said network endpoint, said endpoint being a permitted recipient of said at least one set of connected controlled credentials. 
(D identificiranja unosa (103) povezanog s navedenom ciljanom bilješkom, gdje navedeni unos pripada navedenom najmanje jednom kompletu povezanih kontroliranih vjerodajnica; i (g) dopuštanja preuzimanja navedenog najmanje jednog kompleta povezanih kontroliranih vjerodajnica koji pripada navedenom unosu i dopuštanja puštanja navedenog kompleta povezanih kontroliranih vjerodajnica u navedenu krajnju točku mreže (110), gdje je navedena krajnja točka dopušteni primatelj navedenog najmanje jednog kompleta povezanih kontroliranih vjerodajnica.
a nucleic acid which is at least 95% identical to the nucleic acid of (a). 
(b) nukleinska kiselina koja hibridizira sa nukleinskom kiselinom iz (a) pod vrlo specifičnim uvjetima,
Aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for use in improving the quality of sleep in respiratory patients. 
PATENTNI ZAHTJEVI m» Aklidinij ili bilo koji od njegovih steroizomera ili smjesa stereoizomera ili njegova farmaceutski prihvatljiva sol ili solvat za primjenu u poboljšanju kvalitete sna kod respiratornih bolesnika.
at least one polyethylene oxide and oxycodone hydrochloride, to form a composition; shaping said composition to form the extended release matrix formulation in the form of a tablet by direct compression; 
(2) barem jednog aktivnog agensa, kako bi se formirao sastav; (b) oblikovanje navedenog sastava kako bi se formirala formulacija matrice s produljenim otpuštanjem u obliku tablete pomoću direktne kompresije;
or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (II), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof. 
\ / CF3 ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
The compound or composition of paragraph 13, for administration with a second therapeutic agent selected from a second HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, a nucleoside/nucleotide reverse transcriptase inhibitor, a viral entry inhibitor, an integrase inhibitor, an immune based antiretroviral agent, a viral maturation inhibitor, a cellular inhibitor, or combinations of two or more of the above. 
HIV infekcije kod pacijenta. Spoj ili kompozicija prema zahtjevu 15 za davanje s drugim terapeutskim sredstvom koje se bira od drugog inhibitora HIV proteaze, nenukleozidnog inhibitora reverzne transkriptaze, nukleozidnog/nukleotidnog inhibitora reverzne transkriptaze, inhibitora ulaska virusa, inhibitora integraze, antiretroviralnog imunološkog sredstva, inhibitora sazrijevanja virusa, staničnog inhibitora, ili kombinacija dva ili više gore navedenih.
The inhaler may include a dose or actuation counter to provide an indication of the number of doses dispensed from the canister or, as the number of doses present in a canister when it is hill is known, the number of does remaining in the canister and hence the inhaler. 
Inhalator se može sastojati od brojača doza ili brojača aktiviranja tako da postoji pokazatelj broja doza koje su odmjerene iz spremnika ili, budući da je broj doza u punom spremniku poznat, broj doza koje su preostale u spremniku, odnosno u inhalatoru.
A compound according to any one of claims 1 to 13 for use in the treatment or prophylaxis of pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors. 
17. Spoj prema bilo kojem od zahtjeva 1 do 13, naznačen time, da se upotrebljava u liječenju 1li profilaksi bolova, ateroskleroze, regulacije koštane mase, upale, ishemije, reperfuzijske ozljede, sustavne fibroze, fibroze jetre, fibroze pluća, fibroze bubrega, kronične alogenske nefropatije, kongestivnog srčanog zastoja, infarkta miokarda, sustavne 10
The method according to claim 1, further comprising the step of connecting at least two prefabricated modules to each other in the direction of the length of the modules. 
Postupak sukladno bilo kojem od prethodnih zahtjeva, nadalje sadrži korak spajanja barem dva prethodno proizvedena modula u smjeru duljine modula.
Pharmaceutical composition according to claim 1, wherein the hydrophilic matrix is selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, polyvinyl alcohol, vinyl polymers, alginic acid and its salts and/or polysaccharide polymers. 
Farmaceutski pripravci prema prethodnim patentnim zahtjevima, u kojima je hidrofilni kalup odabran između hidroksipropilceluloze, hidroksipropilmetilceluloze, natrij karboksimctilecluloze, hidroksictilecluloze, karboksivinil polimera, polivinil alkohola, vinilpolimera, alginske kiseline i njenih soli i/ili polisaharidnih polimera.
The method of claim 1, wherein the poly(lactic-co-glycolic acid) comprises 50:50 poly(lactic-co-glycolic acid). 
Sastav za uporabu prema zahtjevu 9, naznačen time, da mikročestice sadrže polimer koji obuhvaća 50:50 poli(laktičku-ko-glikolnu kiselinu).
The method of any preceding embodiment, further comprising enabling access to data services consistently for some or all subscription network identifiers for the subscribed device. 
Postupak prema bilo kom od prethodnih zahtjeva, koji dalje obuhvaća omogućavanje konzistentnog pristupa servisima za podatke za neke ili za sve pretplatničke mrežne identifikacije za pretplatnički uređaj.
R2b and R2c are each independently selected from the group consisting of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and N(CH3)2; 
je neovisno odabrana iz skupine koju čine kloro, fluoro, i bromo; i X je odabrana iz skupine koju čine [image]
The method according to claim 1, wherein the reference tension value is constant. 
navedena referentna vrijednost napetosti je konstanta; i -
The liquefied gas treatment method according to claim 1, wherein the BOG generated in the cargo tank and forcibly vaporized LNG are supplied to and compressed by the compressor (150;13) and are supplied as fuel to at least one of the main engine and the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se BOG, koji se komprimira kompresorom (150;13), te prebaci u izmjenjivač topline (21), komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor.
Novel heterocyclic compounds of the formula I 
PATENTNI ZAHTJEVI 1. Spojevi formule I
A composition according to claim 2, wherein the polymeric moiety is selected from the group consisting of polyethylene glycol (PEG), polyvinyl pyrrolidone (PVP) and polyoxypropylene/polyoxyethylene block copolymers (poloxamers). 
Smjesa prema zahtjevu 2, gdje se polimerni dio izabire iz skupine koja obuhvaća polietilen glikol (PEG), polivinil pirolidon (PVP) 1 polioksipropilen/polioksietilen blok kopolimere (poloksameri).
A compound of the formula (I), wherein A represents a phenyl- or a heterocyclyl-group, wherein the two substituents are in a 1,3-arrangement; or A represents propan-1,3-diyl; 
Spoj formule (I), [image] naznačen time, da A predstavlja fenil- ili heterociklil-skupinu, gdje su dva supstituenta u 1, 3-rasporedu; ili A predstavlja propan-1,3-diil; E predstavlja *-(C1-C4)alkil-O-, -CH=CH- ili [image] gdje zvjezdica označava vezu koja je spojena na R1; Q predstavlja O ili S;
After stirring at room temperature overnight, the solvent is removed in vacuo and the resulting residue is neutralized with saturated sodium bicarbonate solution. 
Nakon miješanje preko noći pri sobnoj temperaturi, otapalo ee odstrani u vakuumu i dobiveni ostatak se neutralizira sa zasićenom otopinom natrijevog bikarbonata.
The reaction is conveniently carried out in a suitable solvent, such as a polar organic solvent, e.g. dimethyl formamide. 
Reakciju se pogodno provodi u pogodnom otapalu, poput polarnog organskog otapala, HR P20080668 T3 primjerice dimetilformamida.
The pharmaceutical composition for use according to claim 2, wherein Ra1 is selected from hydrogen, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, and halogen. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra, odabran od sljedećih: vodik, nesupstituirani C,-Cg alkil, nesupstituirani C,-Cg alkoksi i halogen.
Liquid prepartions for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use. 
Tekuće kompozicije za oralno davanje mogu se također dobiti u obliku suhog praha koji se rekonstituira s pogodnim otapalom prije upotrebe.
A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, of any of claims 1-17 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav sadrži tvar, ili njenu farmaceutski prihvatljivu sol, iz bilo kojeg od patentnih zahtjeva 1-17 1 farmaceutski prihvatljivi nosač.
In a preferred embodiment the rotigotine drug substance comprises at least about 50%, more preferably at least about 70%, of the novel polymorphic form (II) of rotigotine as defined above. 
Rotigotin ljekovita supstanca koja sadrži najmanje 50% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
then converting compound 13 to the compound and 
(m) zatim konverziju spoja 13 u spoj
compressing said blended granules of (e). The mucosal bioadhesive slow release carrier formulation according to claim 1, in which said antiviral agent is acyclovir in an amount of 10 mg to 500 mg. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 10 do 500 mg u navedenom nogaču.
It is therefore a principal object, feature, advantage, and/or aspect of the present invention to provide an apparatus, method, or system of applying a biologically active or chemical substance in relatively small quantities to relatively large volumes of a target product that improves over or solves problems and deficiencies in the art. 
Zbog toga je osnovni cilj, svojstvo, prednost i/ili vid ovog izuma da ostvari jedan uređaj, postupak ili sustav za nanošenje jedne biološki aktivne ili kemijske supstance u relativno malim količinama na relativno veliki volumen ciljnog proizvoda tako da poboljšava ili da rješava probleme i nedostatke u ovom području.
An aqueous binder according to any one of the preceding claims, wherein component (ii) is selected from the group consisting of ammonium sulfamate, calcium sulfamate, sodium sulfamate, potassium sulfamate, magnesium sulfamate, cobalt sulfamate, nickel sulfamate, sodium N-cyclohexyl sulfamate. 
Vodeno vezivo prema bilo kojem od prethodnih zahtjevu, naznačeno time da se komponenta (ii) odabire iz skupine koja se sastoji od amonijeva sulfamata, kalcijeva sulfamata, natrijeva sulfamata, kalijeva sulfamata, magnezijeva sulfamata, kobaltova sulfamata, niklova sulfamata i natrijeva N-cikloheksil sulfamata.
A reliable method to determine the effectiveness of the coating in delaying ripening is to observe the amount and size of brown spots or "sugar spots" that appear an the skin of the banana. 
Pouzdan postupak za određivanje učinkovitosti oblaganja u odlaganju dozrijevanja predstavlja praćenje količine i veličine smeđih točaka ili "šećernih točaka" koje se javljaju na koži banane.
Use of polyethylene glycol in the manufacture of a medicament for reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis by topical administration; wherein the administration period is at least 4 weeks. 
Uporaba polietilen glikola, naznačena time, da je za proizvodnju lijeka za smanjivanje brzine Tecidiva, odgađanje Tecidiva i/ili sprečavanje recidiva herpesa labialis pomoću topikalne primjene; pri čemu je razdoblje primjene najmanje 4 tjedna.
Method as claimed in claim 1, characterized in that the underwater section (12) with the cradle (21) are lifted to within the range of a shore-based crane, lifting equipment of which are attached to the underside of the hull of the swimming vessel, whereby the underwater section (12) with the cradle (21) are picked up by said shore-based crane. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se podvodni dio (12) s gondolom (21) podigne do dosega obalnog krana, čija je oprema za podizanje pričvršćena na donju stranu trupa plovećeg plovila, gdje se podvodni dio (12) s gondolom (21) podigne navedenim obalnim kranom.
The reaction is stirred at -40 °C for about 1 to 2 h to obtain intermediate (b). 
Reakcijsku smjesu miješa se otprilike 1 do 2 sata na -40 *C kako bi se dobilo međuprodukt (b).
A liposome according to claim 5, wherein the antiviral drug is ribavirin. 
Liposom u skladu s patentnim zahtjevom 5, pri čemu je antivirusni lijek ribavirin.
An acetaminophen supersaturated aqueous solution for use as claimed in claim 6 or 7 wherein said local anaesthetic is a short-acting local anaesthetic selected from lidocaine, articaine, oxybuprocaine, chloroprocaine or a medium-acting local anaesthetic selected from prilocaine, mepivacaine, etidocaine or a long-acting local anaesthetic selected from ropivacaine, bupivacaine, cinchocaine, levobupivacaine, proxymetacaine, tetracaine. 
Prezasićena vodena otopina acetaminofena za uporabu prema patentnom zahtjevu 6 ili 7 gdje je navedeni lokalni anestetik - lokalni anestetik sa kratkim djelovanjem izabran od lidokaina, artikaina, oksibuprokaina, kloroprokaina ili lokalni anestetik srednje dužine djelovanja izabran od prilokaina, mepivakaina, etidokaina ili lokalni anestetik sa dugim djelovanjem izabran od ropivakaina, bupivakaina, cinhokaina, levobupivakaina, proksimetakaina, tetrakaina.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 19, naznačen time da je aktivno sredstvo oksikodon hidroklorid i pri čemu oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContin™.
The aqueous pharmaceutical suspension according to claim 7, optionally further comprising, by weight/volume (g/100 mL), about 0.30% to about 0:45% of a flavoring agent. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što izborno dodatno sadrži, težinski/volumno (g/100 ml), otprilike 0,30 % do otprilike 0,45 % sredstva za aromatiziranje.
The system of claim 1, wherein the introducer (102) includes an extending member (110) adapted to be extended through the urethra. 
Sustav prema zahtjevu 1, naznačen time da uvodnik (102) uključuje element za produljivanje (110) koji je prilagođen za produljenje kroz uretru.
In some embodiments of the foregoing, the irradiating step is carried out with a two-dimensional radiation pattern projected into the build region, wherein the pattern varies over time while the concurrently advancing step continues for a time sufficient to form the three-dimensional object. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da se korak ozračivanja provodi s dvodimenzionalnim uzorkom zračenja projiciranim u navedeno područje oblikovanja, gdje spomenuti uzorak varira tijekom vremena, dok se istodobno nastavlja korak odmicanja kroz vrijeme koje je dovoljno da se oblikuje navedeni trodimenzionalni objekt.
A glitazone for use as claimed in claim 1, wherein the said inflammatory respiratory disease is selected from mild asthma, moderate asthma, severe asthma, steroid resistant asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoidosis, silicosis, pulmonary fibrosis, respiratory failure, acute respiratory distress syndrome, emphysema, chronic bronchitis, tuberculosis, and lung cancer. 
Glitazon za uporabu prema zahtjevu 1, naznačen time da je navedena upalna respiratorna bolest odabrana od blage astme, srednje astme, teške astme, astme otporne na steroide, bronhitisa, kronične opstruktivne plućne bolesti (KOPB, cistične fibroze, plućnog edema, plućne embolije, upale pluća, plućne sarkoidoze, silikoze, plućne fibroze, Tespiratornog zatajenja, akutnog respiratornog distresnog sindroma, emfizema, kroničnog bronhitisa, tuberkuloze, te Taka pluća.
A system of any of clauses 23 to 25 wherein the first and second phase contact devices are releasably coupled together. A system of any of clauses 23 to 26 wherein the first and second phase contact devices each comprise releasably interconnected plates, the plates comprising a pair of plates which are in opposed face-to-face relationship and which define between their opposed faces a length of the conduit extending in a direction parallel with the pair of plates, and wherein one plate of the pair of plates of the first phase contact device is shared by the second phase contact device to form one plate of the pair of plates of the second phase contact device. 
Sustav sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačen time, da su prvi i drugi fazno kontaktni uređaji (400, 401) otpustivo spojeni, prvi i drugi faznokontaktni uređaji svaki opcijski obuhvaća odstojno međusobno povezane ploče, te ploče obuhvaćaju par ploča koje su suprotnom odnosu licem u lice i koji između njihovih suprotnih lica definiraju dužinu voda koji se pruža u smjeru paralelnom s parom ploča, i pri čemu jedna ploča od tog para ploča prvog faznokontaktnog uređaja je zajednička s drugim faznokontaktnim uređajem da formira jednu ploču od para ploča drugog faznokontaktnog uređaja.
an operating temperature sensor (105) measuring an operating temperature value, 
- < senzora radne temperature (105) koji mjeri vrijednost radne temperature,
Examples of different environments, applications, and configurations are set forth in Serial Number 10/140,596. 
Primjeri različitih okolina, primjena i konfiguracija iznijeti su u Serial Number 10/140,596.